Switch theme
Sign up to access all valuation multiples
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
2003
2.8K+
LTM Revenue $4.1B
LTM EBITDA $1.4B
$9.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jazz Pharmaceuticals has a last 12-month revenue (LTM) of $4.1B and a last 12-month EBITDA of $1.4B.
In the most recent fiscal year, Jazz Pharmaceuticals achieved revenue of $4.1B and an EBITDA of $1.4B.
Jazz Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jazz Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1B | XXX | $4.1B | XXX | XXX | XXX |
| Gross Profit | $3.8B | XXX | $3.6B | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 89% | XXX | XXX | XXX |
| EBITDA | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBIT | $1.4B | XXX | $727M | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $963M | XXX | $560M | XXX | XXX | XXX |
| Net Margin | 23% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.7B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jazz Pharmaceuticals's stock price is $108.
Jazz Pharmaceuticals has current market cap of $6.7B, and EV of $9.5B.
See Jazz Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.5B | $6.7B | XXX | XXX | XXX | XXX | $14.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jazz Pharmaceuticals has market cap of $6.7B and EV of $9.5B.
Jazz Pharmaceuticals's trades at 2.3x EV/Revenue multiple, and 6.9x EV/EBITDA.
Equity research analysts estimate Jazz Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jazz Pharmaceuticals has a P/E ratio of 6.9x.
See valuation multiples for Jazz Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.7B | XXX | $6.7B | XXX | XXX | XXX |
| EV (current) | $9.5B | XXX | $9.5B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 6.6x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 6.8x | XXX | 13.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.9x | XXX | 11.9x | XXX | XXX | XXX |
| EV/FCF | 6.6x | XXX | 7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJazz Pharmaceuticals's last 12 month revenue growth is 4%
Jazz Pharmaceuticals's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.0M for the same period.
Jazz Pharmaceuticals's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jazz Pharmaceuticals's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jazz Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | -18% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jazz Pharmaceuticals acquired XXX companies to date.
Last acquisition by Jazz Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Jazz Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jazz Pharmaceuticals founded? | Jazz Pharmaceuticals was founded in 2003. |
| Where is Jazz Pharmaceuticals headquartered? | Jazz Pharmaceuticals is headquartered in United States of America. |
| How many employees does Jazz Pharmaceuticals have? | As of today, Jazz Pharmaceuticals has 2.8K+ employees. |
| Who is the CEO of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's CEO is Mr. Bruce C. Cozadd. |
| Is Jazz Pharmaceuticals publicy listed? | Yes, Jazz Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Jazz Pharmaceuticals? | Jazz Pharmaceuticals trades under JAZZ ticker. |
| When did Jazz Pharmaceuticals go public? | Jazz Pharmaceuticals went public in 2007. |
| Who are competitors of Jazz Pharmaceuticals? | Similar companies to Jazz Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's current market cap is $6.7B |
| What is the current revenue of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's last 12 months revenue is $4.1B. |
| What is the current revenue growth of Jazz Pharmaceuticals? | Jazz Pharmaceuticals revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Jazz Pharmaceuticals? | Current revenue multiple of Jazz Pharmaceuticals is 2.3x. |
| Is Jazz Pharmaceuticals profitable? | Yes, Jazz Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's last 12 months EBITDA is $1.4B. |
| What is Jazz Pharmaceuticals's EBITDA margin? | Jazz Pharmaceuticals's last 12 months EBITDA margin is 35%. |
| What is the current EV/EBITDA multiple of Jazz Pharmaceuticals? | Current EBITDA multiple of Jazz Pharmaceuticals is 6.6x. |
| What is the current FCF of Jazz Pharmaceuticals? | Jazz Pharmaceuticals's last 12 months FCF is $1.4B. |
| What is Jazz Pharmaceuticals's FCF margin? | Jazz Pharmaceuticals's last 12 months FCF margin is 35%. |
| What is the current EV/FCF multiple of Jazz Pharmaceuticals? | Current FCF multiple of Jazz Pharmaceuticals is 6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
